In a nutshell This phase 1/2 trial is examining the best dose and side effects of a combined treatment with encorafenib (Braftovi), cetuximab (Erbitux) and nivolumab (Opdivo). The main outcome to be measured will be the tumor response to the treatment. This trial is being conducted in Texas, US. The details Colorectal cancer is one of the leading...
Read MoreCurrent stage-Stage III Posts on Medivizor
Looking for participants with advanced cancer to test a new therapy
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read MoreSearching for patients with advanced solid tumors to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with advanced breast cancer to trial a new treatment.
In a nutshell This trial aims to find out how safe talazoparib (Talzenna) followed by a combination of talazoparib and avelumab (Bavencio) is in patients with advanced breast cancer. The main outcome that will be measured is if patients have side effects. This study is being conducted in Washington, the United States. The...
Read MoreLooking for patients with locally advanced rectal cancer to test a chemotherapy treatment
In a nutshell This phase 2 trial is examining the effectiveness of FOLFOX chemotherapy to treat patients with rectal cancer, without surgery and radiation. The main outcome to be measured will be the tumor response to the treatment. This study is being conducted in New York, US. The details This year an estimated 44,180 people will be diagnosed with...
Read MoreSearching for patients with advanced triple negative breast cancer to trial a new treatment into the tumor
In a nutshell This phase 2 study will investigate Tavokinogene Telseplasmid Electroporation (TTE) in combination with pembrolizumab (Keytruda) in advanced or not suitable for surgery triple-negative breast cancer (TNBC). The main outcome will be the objective response rate (ORR). This trial is recruiting in the United States and...
Read MoreSearching for patients with colorectal cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with colorectal cancer (CRC). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or disappearance). The details A treatment option for patients with...
Read MoreSearching for patients with lung cancer that cannot be operated on to test durvalumab after chemotherapy and radiation
In a nutshell This phase 2 trial will investigate the safety and effectiveness of durvalumab (Imfinzi) in patients with stage III non-small cell lung cancer (NSCLC). The main outcomes will be the number of treatment-related adverse events (TRAEs) and progression-free survival (PFS). The details Non-small cell lung cancer (NSCLC)...
Read MoreLong-term outcomes for dabrafenib plus trametinib treatment for metastatic melanoma.
In a nutshell This study wanted to find out how well patients with advanced melanoma with mutations (abnormal genes) survive when treated with dabrafenib (Tafinlar) and trametinib (Mekinist) combination. The study found that long term, patients survived moderately well with this treatment. Some background Advanced melanoma can be hard to treat. In...
Read MoreLooking patients with advanced cancer to test a new immunotherapy combination
In a nutshell This phase 1/2 trial will investigate BMS-986253, an experimental drug, in combination with nivolumab (Opdivo) to treat advanced cancer. The main outcomes will be the occurrence of side effects and tumor response. The details Advanced cancers have limited treatment options. New drugs are in development to improve patient prognosis. These...
Read More